Publications by authors named "K B Seamon"
Cancer Core Europe brings together the expertise, resources, and interests of seven leading cancer institutes committed to leveraging collective innovation and collaboration in precision oncology. Through targeted efforts addressing key medical challenges in cancer and partnerships with multiple stakeholders, the consortium seeks to advance cancer research and enhance equitable patient care.
View Article and Find Full Text PDFArticle Synopsis
- RAS-driven cancers account for about 30% of human cancers, and RMC-6236 is a promising oral drug that inhibits both mutant and wild-type forms of RAS, showing potential for broad treatment options.
- In preclinical studies, RMC-6236 demonstrated strong anticancer effects, particularly with KRAS mutations, leading to significant tumor shrinkage in mouse models.
- Early results from a phase I/Ib clinical trial indicate that RMC-6236 is effective and tolerable in patients with advanced KRASG12X lung and pancreatic cancers, showing objective responses at a daily dose of 300 mg.
RAS oncogenes (collectively NRAS, HRAS and especially KRAS) are among the most frequently mutated genes in cancer, with common driver mutations occurring at codons 12, 13 and 61. Small molecule inhibitors of the KRAS(G12C) oncoprotein have demonstrated clinical efficacy in patients with multiple cancer types and have led to regulatory approvals for the treatment of non-small cell lung cancer. Nevertheless, KRAS mutations account for only around 15% of KRAS-mutated cancers, and there are no approved KRAS inhibitors for the majority of patients with tumours containing other common KRAS mutations.
View Article and Find Full Text PDFThe discovery of small-molecule inhibitors requires suitable binding pockets on protein surfaces. Proteins that lack this feature are considered undruggable and require innovative strategies for therapeutic targeting. is the most frequently activated oncogene in cancer, and the active state of mutant KRAS is such a recalcitrant target.
View Article and Find Full Text PDFArticle Synopsis
- Knuckle pads are non-cancerous growths that appear as bumps on the joints, mainly at the base of the fingers.
- They can sometimes be mistaken for other skin or joint diseases.
- Treatment options are limited for primary knuckle pads, while those that develop from an external cause often improve when the trigger is removed.